BOSULIF
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
GNR judgment: DEEP_REVIEW. Reference year: 2027. Anchor type: REGULATORY_EXCLUSIVITY. Patent anchor: 2026-06-11. Exclusivity anchor: 2027-03-26. Anchor date: 2027-03-26. Patent tail: yes. Exclusivity tail: yes. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 7417148 | 2025-12-11 | U U-3708 | — | — | — | — | — | — |
| 7417148 | 2025-12-11 | U U-3707 | — | — | — | — | — | — |
| 7919625 | 2025-12-11 | DP — | — | — | — | — | — | — |
| 7417148 | 2026-06-11 | — — | — | — | — | — | 2026-06-11 | — |
| 7417148 | 2026-06-11 | ORANGE_BOOK U-3707,U-3708 | N | Y | DS_EQUIVALENT Claim 1: treatment/inhibition of CML with bosutinib genus, without line, age, or mutation restriction; covers all approved CML indications. | — | 2026-06-11 | — |
| 7919625 | 2026-06-11 | — — | — | — | — | — | 2026-06-11 | — |
| 7919625 | 2026-06-11 | ORANGE_BOOK — | N | N | DP Composition, salt, polymorph, dispersion or formulation claim; no automatic DS-equivalent promotion. | — | 2026-06-11 | — |
| 7767678 | 2026-11-23 | DS/DP — | — | — | — | — | — | — |
| 7767678 | 2027-05-23 | — — | — | — | — | — | 2027-05-23 | — |
| 7767678 | 2027-05-23 | ORANGE_BOOK — | N | N | DP Composition, salt, polymorph, dispersion or formulation claim; no automatic DS-equivalent promotion. | — | 2027-05-23 | — |
| 11103497 | 2034-02-28 | U U-3217 | — | — | — | — | — | — |
| 11103497 | 2034-02-28 | U U-3216 | — | — | — | — | — | — |
| 11103497 | 2034-08-28 | — — | — | — | — | — | 2034-08-28 | — |
| 11103497 | 2034-08-28 | ORANGE_BOOK U-3216,U-3217 | N | N | U Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | — | 2034-08-28 | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| NP | — | 2026-09-26 | — | — | — | — | Source | |
| NP | — | 2026-09-26 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| PED | — | 2027-03-26 | — | — | — | — | Source | |
| PED | — | 2027-03-26 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
| ODE-444 | — | 2030-09-26 | — | — | — | — | Source | |
| ODE-444 | — | 2030-09-26 | Pediatric CP Ph+ CML only; adult uses not covered. | N | N | — | — | Source |
| PED | — | 2031-03-26 | — | — | — | — | Source | |
| PED | — | 2031-03-26 | FDA posted date collected; scope not independently certified; preserved as context/tail. | — | — | — | — | Source |
2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (5)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2026-06-11 | CANONICAL_ANCHOR | Claim 1: treatment/inhibition of CML with bosutinib genus, without line, age, or mutation restriction; covers all approved CML indications. | Source |
| PATENT | 2026-06-11 | HISTORICAL_CONTEXT | Composition, salt, polymorph, dispersion or formulation claim; no automatic DS-equivalent promotion. | Source |
| PATENT | 2027-05-23 | FTO_TAIL | Composition, salt, polymorph, dispersion or formulation claim; no automatic DS-equivalent promotion. | Source |
| PATENT | 2034-08-28 | FTO_TAIL | Process or use limited to a particular indication, combination, regimen, population or formulation; not whole-label anchor. | Source |
| REGULATORY_STATUS | 2026-06-11 | CANONICAL_DECISION | English description not available. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.